/

Karuna Therapeutics, Inc.

KRTX US

KRTX USKaruna Therapeutics, Inc.

United States Composite

329.83

USD

+0.08

(+0.02%)

-15.77EPS Dil.

-20.92P/E

Next Earnings

May 2

Held by Insiders

4.99%

Held by Institutions

86.32%

Short % of Float

5.17%

YTD Yield

63.59%

3Y Yield

197.12%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

- -

Market Capitalization

8,163

6,369

- -

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

1,452

1,365

1,315

Cash, Cash Equivalents & STI

1,437

1,342

1,263

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

-90.91%

Net Income, GAAP

-NaN%

-91.77%

-57.25%

Free Cash Flow

-NaN%

-91.64%

-69.87%

Total Cash Common Dividend

- -

Total Equity

-NaN%

98.92%

11.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-1.10

-1.17

-1.72

-0.94

-4.94

2022

-1.95

-2.17

-2.38

-2.21

-8.74

2023

-2.80

-2.75

-3.16

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. William Meury
Full Time Employees: 339
Sector: Healthcare
Industry: Biotechnology
Address: 99 High Street Boston MA United States 02110
Website: www.karunatx.com
Business: Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Company News

Yahoo
2 months ago
Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term
Yahoo
2 months ago
Chief Medical Officer Stephen Brannan Sells 5,000 Shares of Karuna Therapeutics Inc (KRTX)
Yahoo
2 months ago
Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position

Company Description

CEO: Mr. William Meury
Full Time Employees: 339
Sector: Healthcare
Industry: Biotechnology
Address: 99 High Street Boston MA United States 02110
Website: www.karunatx.com
Business: Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.